Infliximab for rheumatoid arthritis

Expert Review of Clinical Immunology

Volumn 2, Issue 2, 2006, Pages 193-207

  Saleem, Benazir ^a   Mackie, Sarah ^a   Emery, Paul ^a  

^a CHAPEL ALLERTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AUTOANTIBODY; AZATHIOPRINE; C REACTIVE PROTEIN; CHIMERIC ANTIBODY; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; LENERCEPT; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISOLONE; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ACUTE PHASE RESPONSE; ANGIOGENESIS; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CHRONIC INFLAMMATION; CLINICAL PRACTICE; CLINICAL TRIAL; DENDRITIC CELL; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HEART FAILURE; HUMAN; IMMUNOPATHOGENESIS; INFECTION; LUNG FIBROSIS; LYMPHOMA; MACROPHAGE; MONOCYTE; MULTIPLE SCLEROSIS; MYCOBACTERIOSIS; OSTEOCLAST; OUTCOMES RESEARCH; REGULATORY T LYMPHOCYTE; REMISSION; RHEUMATOID ARTHRITIS; SOLID TUMOR; SYNOVITIS; T LYMPHOCYTE; TUBERCULOSIS; VASCULITIS;

EID: 33748512621     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.2.2.193     Document Type: Article

References (139)

1. Spector TD. Rheumatoid arthritis. Rheum. Dis. Clin. North Am. 16, 513-517 (1990).
2. Hochberg MC. Adult and juvenile rheumatoid arthritis: current epidemiological concepts. Epidemiol. Rev. 3, 27-44 (1981).
3. Wiles N, Symmons DP, Harrison B et al. Estimating the incidence of rheumatoid arthritis: trying to hit a moving target? Arthritis Rheum. 42, 1339-1346 (1999).
4. van der Heide A, Jacobs JW, Bijlsma JW et al. The effectiveness of early treatment with second line anti rheumatic drugs. A randomized control trial. Ann. Int. Med. 124, 699-707 (1990).
5. Mottonen T, Hannonen P, Leirisalo-Repo M et al. Comparison of combination therapy with single drug therapy in early RA: a randomized trial. FIN-RACo trial group. Lancet 353, 1568-1573 (1999).
6. O'Dell JR, Haire CE, Erikson N et al. Treatment of RA with methotrexate alone, sulphasalazine and hydroxychloroquine, or a combination of all three medications. N. Engl. J. Med. 334, 1287-1291 (1996).
7. Tugwell P, Pincus T, Yocum D et al. Combination therapy with cyclosporin and methotrexate in severe RA. N. Engl. J. Med. 333, 137-141 (1995).
8. van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br. J. Rheumatol. 34, 74-8 (1995).
9. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344, 907-916 (2001).
10. Elliot MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor versus placebo in RA. Lancet 344, 1105-1110 (1994).
11. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in RA: a randomized controlled study. Ann. Int. Med. 130, 478-86 (1999).
12. Lipsky PE, van der Heijde DMFM, St Clair E et al. Infliximab and methotrexate in the treatment of RA. N. Engl. J. Med. 343, 1549-1602 (2000).
13. Watts AD, Hunt NH, Wanigasekara Y et al. A casein kinase I motif present in the cytoplasmic domain of members of the tumor necrosis factor ligand family is implicated in reverse signalling. EMBO J. 18, 2119-2126 (1999).
14. Buchan G, Barret K, Turner M, Chantry D, Maini RN, Feldmann M. Interleukin 1 and TNF mRNA expression in RA. Clin. Exp. Immunol. 73, 449-455 (1988).
15. Brennan FM, Chantry D, Jackson A et al. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2(8657), 24407 (1989).
16. Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M. Expression of GM-CSF in RA: regulation by TNF-α. Eur. J. Immunol. 21, 2575-2579 (1991).
17. Butler DM, Maini RN, Feldmann M, Brennan FM. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Eur. Cytokine Netw. 6, 225-230 (1995).
18. Williams RO, Feldmann M, Maini RN. Antitumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl Acad. Sci. USA 89, 9784-9788 (1992).
19. Thorbecke GJ, Shah R, Leu C H, Kuruvilla AP, Hardison AM, Palladino MA. Involvement of endogenous tumor necrosis factor-α and transforming growth Factor-β during induction of collagen Type II arthritis in mice. Proc. Natl Acad. Sci. USA 89, 7375-7379 (1992).
20. Piguet PF, Grau EF, Vesin C, Loetscher H, Gentz R, Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with antitumor necrosis factor-α antibody or a recombinant soluble TNF receptor. Immunology 77, 510-514 (1992).
21. Wooley PH, Dutcher R, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor: Fc fusion protein on Type II collagen-induced arthritis in mice. J. Immunol. 151, 6602-6607 (1993).
22. Williams RO, Ghrayeb J, Feldmann M, Maini RN. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with antiCD4. Immunology 84, 433-439 (1995).
23. Kepper J, Probert L, Cazlaris H et al. Transgenic mice expressing human tumor necrosis factor: A predictive genetic model of arthritis. EMBO J. 10, 4025-4931 (1991).
24. Maini R, St.Clair EW, Breedveld F et al. Infliximab (chimeric antitumor necrosis factor-α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT study group. Lancet 354(9194), 1932-1939 (1999).
25. Moreland LW, Baumgartner SW, Schiff MH et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337(3), 141-147 (1997).
26. Lipsky PE, van Der Heijde DM, St. Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Antitumor necrosis factor Trial in Rheumatoid Arthritis with Concomitant Therapy study group. N. Engl. J. Med. 343(22), 1594-1602 (2000).
27. Bromley M, Woolley DE. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid arthritis joint. Arthritis Rheum. 27, 968-975 (1984).
28. Gravallese EM, Manning C, Tsay A et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 43, 250-258 (2000).
29. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176 (1998).
30. Nakagawa N, Kinosaki M, Yamaguchi K et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogensis. Biochem. Biophys. Res. Commun. 253, 395-400 (1998).
31. Hsu H, Lacey DL, Dunstan CR et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl Acad. Sci. USA 96, 3540-3545 (1999).
32. Udegawa N, Takahashi N, Akatsu T et al. Origin of osteoclasts: Mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc. Natl Acad. Sci. USA 87, 7260-7264 (1990).
33. Matsuzaki K, Udagawa N, Takahashi N et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem. Biophys. Res. Commun. 246, 199-204 (1998).
34. Kong YY, Feige U, Sarosi I et al. Activated T-cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402, 304-309 (1999).
35. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Interleukin-1-β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25, 255-259 (1999).
36. Kimble RB, Srivastava S, Ross FP, Matayoshi A, Pacifici R. Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1 and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. J. Biol. Chem. 271, 28890-28897 (1996).
37. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106, 1481-1488 (2000).
38. Van den Berg WB. Uncoupling of inflammatory and destructive mechanisms in arthritis. Semin. Arthritis Rheum. 30(Suppl. 2), 7-16 (2001).
39. Pettit AR, Ji H, von Stechow D et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am. J. Pathol. 159, 1689-1699 (2001).
40. Redlich K, Hayer S, Maier A et al. Tumor necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum. 46, 785-792 (2002).
41. Redlich K, Hayer S, Ricci R et al. Osteoclasts are essential for TNF-α-mediated joint destruction. J. Clin. Invest. 110, 1419-1427 (2002).
42. Holstead-Jones D, Kong YY, Penninger JM. Role of RANKL and RANK in bone loss and arthritis. Ann. Rheum. Dis. 61(Suppl. II), 32-39 (2002).
43. Baier A, Meineckel I, Gay S, Pap T. Apoptosis in rheumatoid arthritis. Curr. Opin. Rheumatol. 15, 274-279 (2003).
44. Lui H, Pope RM. The role of apoptosis in rheumatoid arthritis. Curr. Opin. Pharmacol. 3, 317-322 (2003).
45. Muller-Ladner U, Gay RE, Gay S. The role of nuclear factor κB in synovial inflammation. Curr. Rheumatol. Rep. 4, 201-207 (2002).
46. Van der Brande JM, Braat H, van den Brink GH et al. Infliximab not etanercept induces apoptosis in the lamina propria T lymphocytes from patients with Crohn's disease. Gastroenterology 121, 1145-1157 (2001).
47. Cope AP. Exploring the reciprocal relationship between immunity and inflammation in chronic inflammatory arthritis. Rheumatology 42, 716-731 (2003).
48. - T-cell compartment in peripheral blood in patients with rheumatoid arthritis. Rheumatol. Int. 24(6), 351-354 (2004).
49. Nahar IK, Shojania K, Marra CA, Alamgir AH, Anis AH. Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann. Pharmacother. 37, 1256-1265 (2003).
50. Knight DM, Trinh H, Le J et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 30, 1443-1453 (1993).
51. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 7, 251-259 (1995).
52. Harriman G. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti TNF α treatment. Ann. Rheum. Dis. 58(Suppl. 1), 161-164 (1999).
53. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of tumor necrosis factor α blocking agents adalimumab, etanercept and infliximab when added to methotrexate in patients with active RA. Ann. Rheum. Dis. 62(Suppl. 2), 13-16 (2003).
54. Mitoma H, Horiuchi T, Hatta N et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α. Gastroenterology 128(2), 376-392 (2005).
55. St Clair EW, Wagner CL, Fasanmade AA et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 1451-1459 (2002).
56. Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 59, 1342-1359 (2000).
57. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of antitumor necrosis factor-α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41, 1552-1563 (1998).
58. Elliot MJ, Maini RN, Feldmann M et al. Treatment of RA with chimeric monoclonal antibodies to tumor necrosis factor. Arthritis Rheum. 36, 1681-1690 (1993).
59. Tak PP, Taylor PC, Breedveld FC et al. Decrease in cellularity and expression of adhesion molecules by antitumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum. 39, 1077-1081 (1996).
60. Taylor PC, Peters AM, Paleolog E et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis. Arthritis Rheum. 43, 38-47 (2000).
61. van Oosterhout M, Levarht EW, Sont JK et al. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF and IL18 but not CXCL12. Ann. Rheum. Dis. 64, 537-543 (2005).
62. Kawashima M, Miossec P. Effect of treatment of rheumatoid arthritis with infliximab on IFN, IL4, T-bet, and GATA-3 expression: link with improvement of systemic inflammation and disease activity Ann. Rheum. Dis. 64, 415-418 (2005).
63. Lorenz HM, Antoni C, Valerius T et al. In vivo blockade of TNF-α by intravenous infusion of a chimeric monoclonal TNF-α antibody in patients with rheumatoid arthritis. Short-term cellular and molecular effects. J. Immunol. 156, 1646-1653 (1996).
64. Buckley CD, Amft N, Bradfield PF et al. Persistent induction of the chemokine receptor CXCR4 by TGF-β 1 on synovial T-cells contributes to their accumulation within the rheumatoid synovium. J. Immunol. 165, 3423-3429 (2000).
65. Aeberli D, Seitz M, Jüni P, Villiger PM. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-α inhibitors Rheumatology 44, 172-175 (2005).
66. + T-cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum. 42, 2166-2173 (1999).
67. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50(2), 206-211 (2002).
68. Pilling D, Akbar AN, Girdlestone J et al. Interferon-β mediates stromal cell rescue of T cells from apoptosis. Eur. J. Immunol. 29, 1041-1050 (1999).
69. Van den Brande JM, Braat H, van den Brink GR et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124, 1774-1785 (2003).
70. Ehrenstein MR, Evans JG, Singh A et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti TNF therapy. J. Exp. Med. 200, 277-285 (2004).
71. + T cells in patients with active rheumatoid arthritis is reduced by infliximab. Ann. NY Acad. Sci. 1051, 506-514 (2005).
72. De Rycke L, Baeten D, Foell D et al. Differential expression and response to antiTNF-α treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. J. Pathol. 206(1), 17-27 (2005).
73. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121(5), 1145-1157 (2001).
74. Smeets TJ, Kraan MC, van Loon ME et al. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum. 48, 2155-2162 (2003).
75. Catrina AI, Trollmo C, Klint E et al. Evidence that antitumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report. Arthritis Rheum. 52, 61-72 (2005).
76. Kirchner S, Holler E, Haffner S, Andreesen R, Eissner G. Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine 28(2), 67-74 (2004).
77. Lee CK, Lee EY, Chung SM, Mun SH, Yoo B, Moon HB. Effects of disease-modifying antirheumatic drugs and anti-inflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor κB, osteoprotegerin, and receptor activator of nuclear factor κB ligand. Arthritis Rheum. 50(12), 3831-3843 (2004).
78. Kurowska M, Kurowska M, Radzikowska A et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after antitumor necrosis factor-α treatment. Arthritis Rheum. 46, 1744-1753 (2002).
79. Via CS, Shustov A, Rus V et al. In vivo neutralization of TNF-α promotes humoral autoimmunity by preventing the induction of CTL. J. Immunol. 167, 6821 (2001).
80. D'Auria F, Rovere-Querini P, Giazzon M et al. Accumulation of plasma nucleosomes upon treatment with antitumor necrosis factor-α antibodies. J. Intern. Med. 255(3), 409-418 (2004).
81. De Miguel S, Jover JA, Vadillo C, Judez E, Loza E, Fernandez-Gutierrez B. B cell activation in rheumatoid arthritis patients under infliximab treatment. Clin. Exp. Rheumatol. 21(6), 726-732 (2003).
82. Ferraccioli GF, Assaloni A, Di Poi E et al. Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trial. Rheumatology 41, 1109-1112 (2002).
83. Caramaschi P, Biasi D, Tonolli E et al. Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment Rheumatol. Int. 26(1), 58-62 (2005).
84. Allanore Y, Sellam J, Batteux I et al. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin. Exp. Rheum. 22, 756-758 (2004).
85. Alessandri C, Bombardieri M, Papa N et al. Decrease of anticyclic citrullinated peptide antibodies and rheumatoid factor following antiTNF therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann. Rheum. Dis. 63, 1218-1221 (2004).
86. Yazdani-Buiki B, Stadlmaier E, Mulabecivovic A et al. Blockade of tumor necrosis factor α significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis. Ann. Rheum. Dis. 64(8), 1224-1226 (2005).
87. van Lieshout AWT, Barrera P, Smeets RL et al. Inhibition of TNF-α during maturation of dendritic cells results in the development of semi-mature cells: a potential mechanism for the beneficial effects of TNF-α blockade in rheumatoid arthritis. Ann. Rheum. Dis. 64, 408-414 (2005).
88. Grundmann S, Hoefer IE, Ulusans S et al. Antitumor necrosis factor-α therapies attenuate adaptive arteriogenesis in the rabbit. Am. J. Physiol. Heart Circ. Physiol. 289(4), H1497-H1505 (2005).
89. Boers M, Verhoeven AC, Markusse MH et al. Randomised comparison of combined step down prednisolone, methotrexate, and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350, 309-318 (1997).
90. Grigor C, Capell H, Stirling A et al. Effect of treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind radomised controlled trial. Lancet 364, 263-269 (2004).
91. Pincus T, Ferraccioli G, Sokka T et al. Evidence from clinical trials and long-term observational studies that DMARDs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology 41, 1346-1356 (2002).
92. Molennar ET, Voskuly AE, Dinant HJ et al. Progression of radiological damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum. 50, 36-42 (2004).
93. Mulherin D, Fitzgerald O, Bresnihan B. Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ. Br. J. Rheumatol. 35, 1263-1268 (1996).
94. Elliot MJ, Maini RN, Feldmann M et al. Repreated therapy with monoclonal antibody to tumor necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 344, 1125-1127 (1994).
95. Williams RO, Mason LJ, Feldmann M, Maini RN. Synergy between antiCD4 and tumor necrosis factor in the amelioration of established collagen induced arthritis. Proc. Natl Acad. Sci. USA 91, 2762-2766 (1994).
96. Weinblatt ME, Coblyn JS, Fox DA et al. Efficacy of low dose methotrexate in RA. N. Engl. J. Med. 312, 818-822 (1985).
97. Weinblatt ME, Kaplan H, Germain BF et al. Methotreate in rheumatoid arthritis: a five year prospective study. Arthritis Rheum. 37, 1492-1498 (1994).
98. Pincus T, Yazici Y, Sokka T et al. Methotrexate as the 'anchor drug' for the treatment of early rheumatoid arthritis. Clin. Exp. Rheum. 21(Suppl. 31), S179-S185 (2003).
99. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti tumor necrosis factor monoclonal antibody combined with low dose methotrexate in RA. Arthritis Rheum. 41, 1552-1563 (1998).
100. Ware JE, Konsinski M, Keller SK et al. SF-36 physical and mental health summary scales: a user's manual. Boston: Health Institute (1994).
101. van der Heijde D. Plain X rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability. Baillieres Clin. Rheumatol. 10, 435-453 (1996).
102. Smolen JS, Han C, Bala M et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in RA patients who had no clinical improvement. Arthritis Rheum. 52, 1020-1030 (2005).
103. St Clair WE, van der Heijde DM, Smolen JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. Arthritis Rheum. 50, 3432-3443 (2004).
104. Quinn MA, Conaghan PG, O'Connor PJ et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 52(1), 27-35 (2005).
105. ten Wolde S, Breedveld FC, Hermans J etal. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet. 347(8998), 347-352 (1996).
106. Buch MH, Marzo-Ortega H, Bingham SJ, Emery P. Long-term treatment of rheumatoid arthritis with tumor necrosis factor blockade: outcome of ceasing and restarting biologicals. Rheumatology 43, 243-244 (2004).
107. DeVries JR, Goekoop-Ruiterman YPM, Van Zeben D et al. A comparison of clinical and radiological outcomes of four treatment strategies for early rheumatoid arthritis: results of the BeST trial. (2004) (Eular Abstract OP0001).
108. Mugnier B. Factors predicting responsiveness to anti TNF therapy in patients with rheumatoid arthritis: using biotherapies rationally. Joint Bone Spine 71, 91-94 (2004).
109. Wolbink GJ, De Groot E, Lems WF et al. Relationship between serum levels of infliximab, CRP and clinical response to infliximab patients with rheumatoid arthritis. Ann. Rheum. Dis. 62(S1), 98 (2003) (Abstract).
110. Buch MH, Seto Y, Bingham SJ et al. C reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum. 52, 42-48 (2005).
111. Edrees AF, Misra SN, Abduou NI. Anti-tumor necrosis factor therapy in rheumatoid arthritis: correlation of TNF serum levels with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin. Exp. Rheumatol. 23, 469-474 (2005).
112. Stern R, Wolfe F. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J. Rheumatol. 31, 1538-1545 (2004).
113. Genovese M, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor inhibition. N. Engl. J. Med. 353, 1114-1123 (2005).
114. REFLEX study 'Randomized evaluation of long-term efficacy of rituximab in RA'. Due for presentation at American College of Rheumatology, CA, USA (2005).
115. Hyrich KL, Silman AJ, Watson KD, Symmons DP. Antitumor necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann. Rheum. Dis. 63(12), 1538-1543 (2004).
116. Maillard H, Ornetti P, Grimault L et al. Severe pyogenic infections in patients taking infliximab: a regional cohort study. Joint Bone Spine. 72(4), 330-334 (2005).
117. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med. 345, 1098-1104 (2001).
118. Wallis RS, Broder MS, Wong JY, Hanson JY, Beenhouwer DO. Granulomatous infectious diseases associated with TNF antagonists. Clin. Infect. Dis. 38(9), 1261-1265 (2004).
119. Keane J. TNF blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 44, 714-720 (2005).
120. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 48, 2122-2127 (2003).
121. Olleros ML, Guler R, Corazza N et al. Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-α. J. Immunol. 168(7), 3394-3401 (2002).
122. Mohan VP, Scanga CA, Yu K et al. Effects of tumor necrosis factor-α on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect. Immun. 69(3), 1847-1855 (2001).
123. Carmono L, Gomez-Reino JJ, Vicente Rodríguez-Valverde et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 52, 1766-1772 (2005).
124. Symmons DPM, Silman AJ. Anti-TNF therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer. Arthritis Rheum. 50, 1703-1706 (2004).
125. Geborek P, Bladstrom A, Turesson C et al. tumor necrosis factor blockers do not increase overall tumor risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann. Rheum. Dis. 64(5), 699-703 (2005).
126. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the AntiTNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107, 3133-3140 (2003).
127. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Intern. Med. 138, 807-811 (2003).
128. Mohan N, Edwards ET, Cupps TR et al. Demyelination occurring during antitumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum. 44, 2862-2869 (2001).
129. Atzeni F, Turiel M, Capsoni F et al. Autoimmunity and antiTNF-α agents. Ann. NY Acad. Sci. 1051, 559-569 (2005).
130. Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res. Ther. 6(3), R264-R272 (2004).
131. Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study Arthritis Res. Ther. 6(6), R535-R543 (2004).
132. Ferraccioli G, Gremese E. Thrombogenicity of TNF α in rheumatoid arthritis defined through biological probes: TNF α blockers. Autoimmun. Rev. 3(4), 261-266 (2004).
133. Charles PJ, Smeenk RJ, De Jong J et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients, following treatment with infliximab, a monoclonal antibody to tumor necrosis factor a: findings in open-label and randomised placebo-controlled trials. Arthritis Rheum. 43, 2383-2390 (2000).
134. Elkayam O, Caspi D. Infliximab induced lupus in patients with rheumatoid arthritis. Clin. Exp. Rheum. 22(4), 502-3 (2004).
135. Jarrett SJ, Cunnane G, Conaghan PG et al. Antitumor necrosis factor-α therapy-induced vasculitis: case series. J. Rheumatol. 30, 2287-2291 (2003).
136. Stokes MB, Foster K, Markowitz GS et al. Development of glomerulonephritis during antiTNF-α therapy for rheumatoid arthritis. Nephrol. Dial. Transplant. 20, 1400-1406 (2005).
137. Jonsdottir T, Forslid J, van Vollenhoven A et al. Treatment with tumor necrosis factor α antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann. Rheum. Dis. 63, 1075-1078 (2004).
138. Ostor AJK, Crisp AJ, Somerville MF, Scott DGI. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. Br. Med. J. 329, 1266 (2004).
139. Courtney PA, Alderdice J, Whitehead EM. Comment on methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum. 49, 617 (2003).